← The Wire
IMVTNasdaq
Immunovant, Inc.
Biological Products, (No Diagnostic Substances) · DE · CIK 1764013
Developing IMVT-1402 to treat autoimmune diseases by inhibiting FcRn and reducing pathogenic IgG antibodies
$6.90B
Market cap
$38.51
Last close
-0.9%
1D
+1.1%
5D
1.3M
Volume
Price · last 39 sessions+38.3%
May 4L $26.29 · H $38.85Jun 29
157
Total filings
May 20, 2026
Last filing
03/31
Fiscal year end
10-K10-KMay 20, 20268-KResults of OperationsMay 20, 202610-Q10-QFeb 6, 20268-KResults of OperationsFeb 6, 20268-KCompany UpdateDec 12, 2025424B5424B5Dec 12, 2025SC 13D/ASC 13D/ADec 12, 20258-KCompany UpdateDec 11, 20258-KExecutive ChangeNov 21, 202510-Q10-QNov 10, 20258-KResults of OperationsNov 10, 20258-KReg FD Disclosure · Company UpdateSep 3, 20258-KShareholder VoteAug 28, 202510-Q10-QAug 11, 20258-KResults of OperationsAug 11, 20258-KExecutive ChangeJul 29, 2025DEFA14ADEF 14AJul 9, 2025DEF 14ADEF 14AJul 9, 202510-K10-KMay 29, 20258-KResults of OperationsMay 29, 20258-KExecutive Change · Reg FD DisclosureApr 21, 20258-KReg FD Disclosure · Company UpdateMar 19, 202510-Q10-QFeb 6, 20258-KResults of OperationsFeb 6, 20258-KCompany UpdateJan 24, 20258-KReg FD DisclosureJan 14, 20258-KMaterial Agreement · Equity IssuanceJan 13, 202510-Q10-QNov 7, 20248-KResults of Operations · Company UpdateNov 7, 20248-KReg FD Disclosure · Company UpdateSep 9, 20248-KShareholder VoteAug 13, 202410-Q10-QAug 6, 20248-KResults of OperationsAug 6, 2024DEFA14ADEFA14AJun 26, 2024DEF 14ADEF 14AJun 26, 202410-K10-KMay 29, 20248-KResults of OperationsMay 29, 202410-Q10-QFeb 12, 20248-KResults of OperationsFeb 12, 2024SC 13GSC 13GFeb 9, 20248-KReg FD DisclosureJan 9, 20248-KReg FD Disclosure · Company UpdateDec 20, 20238-KReg FD Disclosure · Company UpdateNov 28, 202310-Q10-QNov 9, 20238-KResults of OperationsNov 9, 2023424B5424B5Sep 29, 20238-KMaterial Agreement · Equity IssuanceSep 28, 2023424B5424B5Sep 26, 20238-KReg FD Disclosure · Company UpdateSep 26, 20238-KShareholder VoteAug 23, 202310-Q10-QAug 10, 20238-KResults of OperationsAug 10, 2023DEFA14ADEFA14AJun 26, 2023DEF 14ADEF 14AJun 26, 202310-K10-KMay 22, 20238-KResults of Operations · Company UpdateMay 22, 20238-KCompany UpdateMar 27, 202310-Q10-QFeb 3, 20238-KResults of OperationsFeb 3, 20238-KCompany UpdateJan 9, 20238-KReg FD DisclosureDec 8, 202210-Q10-QNov 4, 20228-KResults of OperationsNov 4, 2022424B5424B5Oct 5, 20228-KMaterial Agreement · Company UpdateOct 4, 20228-KReg FD Disclosure · Company UpdateSep 28, 20228-KReg FD Disclosure · Company UpdateSep 7, 20228-KShareholder VoteAug 19, 202210-Q10-QAug 5, 20228-KResults of OperationsAug 5, 2022DEFA14ADEFA14AJun 30, 2022DEF 14ADEF 14AJun 30, 202210-K10-KJun 8, 20228-KResults of Operations · Reg FD DisclosureJun 8, 20228-KReg FD DisclosureMar 30, 2022SC 13GSC 13GFeb 11, 202210-Q10-QFeb 4, 20228-KResults of OperationsFeb 4, 20228-KReg FD DisclosureJan 7, 20228-KReg FD DisclosureJan 5, 2022
Insider Activity
In the 90 days to Mar 18, 2026: 3 sold $536K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 18, 2026 | Van Tuyl ChristopherChief Legal Officer | Sell | 2,877 | $24.97 | $72K |
| Feb 25, 2026 | Gloria MelanieChief Operating Officer | Sell | 1,437 | $26.98 | $39K |
| Feb 25, 2026 | Gloria MelanieChief Operating Officer | Sell | 942 | $28.90 | $27K |
| Feb 25, 2026 | Gloria MelanieChief Operating Officer | Sell | 859 | $28.16 | $24K |
| Jan 21, 2026 | Stout Jay SChief Technology Officer | Sell | 1,977 | $26.03 | $51K |
| Jan 7, 2026 | Stout Jay SChief Technology Officer | Sell | 1,148 | $26.51 | $30K |
| Jan 7, 2026 | Stout Jay SChief Technology Officer | Sell | 55 | $26.92 | $1K |
| Dec 18, 2025 | Van Tuyl ChristopherChief Legal Officer | Sell | 8,529 | $26.78 | $228K |
| Dec 18, 2025 | Van Tuyl ChristopherChief Legal Officer | Sell | 2,284 | $27.38 | $63K |
| Dec 12, 2025 | Roivant Sciences Ltd.Director,TenPercentOwner | Buy | 16,666,666 | $21.00 | $350.0M |
| Dec 1, 2025 | Fromkin Andrew J.Director | Sell | 19,351 | $23.14 | $448K |
| Dec 1, 2025 | Hughes Douglas J.Director | Sell | 13,091 | $23.14 | $303K |
| Dec 1, 2025 | Fromkin Andrew J.Director | Sell | 2,898 | $23.95 | $69K |
| Dec 1, 2025 | Hughes Douglas J.Director | Sell | 1,909 | $23.96 | $46K |
| Nov 20, 2025 | Gloria MelanieChief Operating Officer | Sell | 10,251 | $23.54 | $241K |
| Nov 20, 2025 | Gloria MelanieChief Operating Officer | Sell | 2,375 | $23.97 | $57K |
| Oct 22, 2025 | Geffner MichaelChief Medical Officer | Sell | 2,595 | $19.03 | $49K |
| Oct 22, 2025 | Stout Jay SChief Technology Officer | Sell | 2,520 | $19.03 | $48K |
| Oct 8, 2025 | Stout Jay SChief Technology Officer | Sell | 1,585 | $16.30 | $26K |
| Oct 8, 2025 | Geffner MichaelChief Medical Officer | Sell | 1,272 | $16.30 | $21K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
In the News
Barron's2 Biotech Stocks Are Surging Today Thanks to This Arthritis Drug1mo agoBarron'sNvidia, Astera Labs, Micron, Intel, United, Hasbro, Toll, Immunovant, Analog Devices, and More Movers1mo agoInvestor's Business DailyThese Two Biotech Stocks Rocketed — And One Just Broke Out1mo ago
Reputable outlets only (Reuters, WSJ, CNBC, Barron's, and peers). More on Google News ↗
Similar companies
Comparable business profile · signals at a glance